Journal of the American Heart Association, 2021 Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation.
Robert Rose +2 more
exaly +3 more sources
Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis [PDF]
Cancer MedicineBackground Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection.
Anna Homeniuk +3 more
doaj +2 more sources
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study [PDF]
Annals of HematologyAcalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved in multiple countries for patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is approved in China for patients with CLL who received ≥ 1 prior therapy.
Jia Li +13 more
doaj +2 more sources
Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease [PDF]
Frontiers in ImmunologyBackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only curative option for certain malignant hematopoietic disorders, yet its benefits are limited by the development of graft-versus-host disease (GVHD).
Vasantharaja Raguraman +11 more
doaj +2 more sources
International Journal of Infectious DiseasesObjectives: Ibrutinib, a first-generation covalent Bruton's tyrosine kinase inhibitor (BTKi) was found to be a risk factor for the occurrence of invasive fungal complications.
Nicolas Stocker +2 more
exaly +3 more sources
Frontiers in Oncology, 2021 The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chronic lymphocytic
Jaeyong Jung, Sining Zhu, Ping Xie
exaly +3 more sources
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL [PDF]
Oncology and TherapyIntroduction There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL).
Daniel A. Ermann +12 more
doaj +2 more sources
Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral–BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens [PDF]
PharmaceuticsObjectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking.
Lu Chen +5 more
doaj +2 more sources
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma [PDF]
Blood Advances: This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in ...
Tycel Phillips +7 more
doaj +2 more sources
Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials [PDF]
Journal of Immunotherapy and Precision Oncology, 2022 Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects.
Thura Win Htut +2 more
doaj +1 more source